Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT03910543
Phase
PHASE1
Status
Completed

Conditions

  • Cutaneous Sarcoidosis
  • Granuloma Annulare

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

Study Details

To investigate the ability of tofacitinib, a Janus kinase (JAK) inhibitor, to treat patients with cutaneous sarcoidosis and granuloma annulare during 6 months of therapy.

Key Dates

Start date
Apr 11, 2019
Status verified
Jul 2021
Primary completion
Jun 1, 2021
Completion
Jun 1, 2021

Study Design

Enrollment
15 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Patients with Cutaneous Sarcoidosis
    Patients with cutaneous sarcoidosis that may also have also have internal organ sarcoidosis
  • Experimental: Patients with Granuloma Annulare
    Patients with granuloma annulare that is long-standing and/or widespread

Primary Outcome Measure

Change in Cutaneous Sarcoidosis Activity and Morphology Instrument (CSAMI) [ Time Frame: 6 - 12 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Yale Center for Clinical InvestigationNew HavenConnecticut06519-

Find similar trials in New Haven, CT

By research site
Yale Center for Clinical Investigation· New Haven, CT

Related Studies